Comments
Loading...

Bellerophon Therapeutics

BLPHOTCEM
$0.102500
-0.05-50.24%
At close: Jul 19, 10:48 AM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$2.00
Lowest Price Target1
$2.00
Consensus Price Target1
$2.00

Bellerophon Therapeutics (OTC:BLPH) Stock, Analyst Ratings, Price Targets, Forecasts

Bellerophon Therapeutics Inc has a consensus price target of $2 based on the ratings of 2 analysts. The high is $2 issued by HC Wainwright & Co. on June 6, 2023. The low is $2 issued by HC Wainwright & Co. on June 6, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Laidlaw & Co. on June 6, 2023, May 17, 2023, and May 9, 2023, respectively. With an average price target of $22.33 between HC Wainwright & Co., HC Wainwright & Co., and Laidlaw & Co., there's an implied 43690.85% upside for Bellerophon Therapeutics Inc from these most-recent analyst ratings.

Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for Bellerophon Therapeutics

Buy NowGet Alert
06/06/2023Buy Now3821.57%HC Wainwright & Co.
Andrew Fein
$30 → $2MaintainsBuyGet Alert
06/06/2023Buy NowLaidlaw & Co.
Yale Jen
DowngradeBuy → HoldGet Alert
05/17/2023Buy Now58723.53%HC Wainwright & Co.
Andrew Fein
→ $30ReinstatesBuy → BuyGet Alert
05/09/2023Buy Now68527.45%Laidlaw & Co.
Yale Jen
→ $35Initiates → BuyGet Alert
04/04/2023Buy Now58723.53%HC Wainwright & Co.
Andrew Fein
→ $30Reiterates → BuyGet Alert

FAQ

Q

What is the target price for Bellerophon Therapeutics (BLPH) stock?

A

The latest price target for Bellerophon Therapeutics (OTCEM:BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 3821.57% upside). 0 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Bellerophon Therapeutics (BLPH)?

A

The latest analyst rating for Bellerophon Therapeutics (OTCEM:BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics maintained their buy rating.

Q

When was the last upgrade for Bellerophon Therapeutics (BLPH)?

A

There is no last upgrade for Bellerophon Therapeutics

Q

When was the last downgrade for Bellerophon Therapeutics (BLPH)?

A

The last downgrade for Bellerophon Therapeutics Inc happened on June 6, 2023 when Laidlaw & Co. changed their price target from N/A to N/A for Bellerophon Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Bellerophon Therapeutics (BLPH)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.

Q

Is the Analyst Rating Bellerophon Therapeutics (BLPH) correct?

A

While ratings are subjective and will change, the latest Bellerophon Therapeutics (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics (BLPH) is trading at is $0.05, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.